Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Conference News TCT 2025

More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain

Yael L. Maxwell

October 26, 2025

News Features

Imperfect Evidence: How Strong Is the Case for Transcatheter Tricuspid Valve Interventions?

Todd Neale

October 22, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Conference News NY Valves 2025

Changes in Quality of Life Mirror TR Reductions After Tricuspid Procedures: Tri-QOL

Yael L. Maxwell

July 01, 2025

News Conference News TCT 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Michael O'Riordan

October 30, 2024

News Conference News TCT 2024

TRILUMINATE: More Patient Data Reassure on TEER’s Benefits for Severe TR

Michael O'Riordan

October 29, 2024

News Features

Valvular Heart Disease Has a Diversity Problem

Yael L. Maxwell

July 12, 2024

News Daily News

Inequities in Mitral, Tricuspid Trials Have Implications Across CV Research

Yael L. Maxwell

December 12, 2022

News Conference News PCR London Valves 2022

Will Tricuspid Innovation Outpace Mitral? Some Hopes, Some Second-Guessing

Shelley Wood

December 07, 2022

News Daily News

Frailty Before Cardiac Surgery Common, Linked to Adverse Outcomes

Michael O'Riordan

September 13, 2022

News Features TVT 2022

Minorities, Poorer Patients Missing Out on Structural Heart Care

Michael O'Riordan

June 15, 2022

News Conference News ACC 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Yael L. Maxwell

April 05, 2022

News Opinion Fellow Talk

Pursuing Training in Structural Heart Interventions: Q&A With Mario Gössl, MD

Yashasvi Chugh, MD

August 05, 2019

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

Advertisement

More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain

Imperfect Evidence: How Strong Is the Case for Transcatheter Tricuspid Valve Interventions?

CVD Still the Leading Cause of Death and Disease Globally

Changes in Quality of Life Mirror TR Reductions After Tricuspid Procedures: Tri-QOL

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

TRILUMINATE: More Patient Data Reassure on TEER’s Benefits for Severe TR

Valvular Heart Disease Has a Diversity Problem

Inequities in Mitral, Tricuspid Trials Have Implications Across CV Research

Will Tricuspid Innovation Outpace Mitral? Some Hopes, Some Second-Guessing

Frailty Before Cardiac Surgery Common, Linked to Adverse Outcomes

Minorities, Poorer Patients Missing Out on Structural Heart Care

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Pursuing Training in Structural Heart Interventions: Q&A With Mario Gössl, MD

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content